New Two-Drug attack on tough bladder cancer shows promise
NCT ID NCT07241793
Summary
This study is testing whether a new drug, either alone or combined with an immunotherapy drug, can help control advanced bladder cancer that has spread and has a specific marker called HER2. It will involve about 96 adults whose cancer has progressed despite prior treatments. The main goal is to see if the treatment shrinks tumors and is safe for patients.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UROTHELIAL CARCINOMA RECURRENT are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sun yat-sen university cancer center
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Second Affiliated Hospital of Kunming Medical University
RECRUITINGKunming, Yunnan, 650033, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The fifth Affiliated Hospital of Guangzhou Medcial University
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Tongji Hospital, Affiliated to Tongji Medical College of Huazhong University of Science and Technology
RECRUITINGWuhan, Hubei, 430030, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.